Lantheus to Sell CDMO Business and Springfield Facility to PharmaLogic
Lantheus agreed to sell its CDMO business and a New Jersey facility to PharmaLogic. The deal is subject to closing conditions and includes a long-term supply agreement for lutetium Lu 177 dotatate. Lantheus will provide transition services post-closing, according to an SEC filing.
How this was made
The 30-second read
Why it matters
The transaction removes a non‑core segment, likely leading to a short‑term price dip, but the accompanying supply agreement may mitigate revenue loss.
Market read
Primary M&A disclosure for a listed biotech; traders may adjust positions based on expected cash proceeds and operational focus.
What to watch
Potential strategic focus on core radiopharmaceuticals could improve long‑term margins.
Background
Lantheus Holdings (LNTH) filed an 8‑K on Nov. 9, 2026 announcing the sale of its CDMO business and a New Jersey manufacturing site to PharmaLogic, with transition services and a supply agreement for lutetium Lu‑177 dotatate.
Ticker impact
Lantheus announced the sale of its CDMO business and Springfield facility to PharmaLogic, a primary disclosure of a divestiture.
potential modest downside as the market prices in the asset sale
First report of the transaction; investors typically react to loss of a business segment unless the deal price is disclosed as highly accretive.
Market effects
May signal consolidation in the CDMO space and could affect peers in contract manufacturing.
Limited to U.S. biotech and pharma manufacturing sector.
Low global impact beyond the niche CDMO market.
Counterpoint
If the sale price is significantly above market, the stock could rally on cash infusion expectations.
Key entities
- CompanyLantheus Holdings, Inc.
US‑listed biotech firm selling its CDMO business.
- CompanyPharmaLogic
Private contract manufacturing organization acquiring Lantheus' CDMO assets.
